(Albany), DelveInsight’s “Molluscum Contagiosum Pipeline Insight 2023” report offers extensive knowledge on more than 10+ companies and 10+ pipeline drugs within the landscape of Molluscum Contagiosum research. The Molluscum Contagiosum Pipeline report provides detailed profiles of the Molluscum Contagiosum pipeline drugs, encompassing both Molluscum Contagiosum clinical trials and nonclinical stage products. Additionally, it assesses the therapeutics based on product type, stage, route of administration, and molecule type. Furthermore, the report sheds light on inactive pipeline products in this field.
In the Molluscum Contagiosum Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Molluscum Contagiosum clinical trials studies, Molluscum Contagiosum NDA approvals (if any), and product development activities comprising the technology, Molluscum Contagiosum collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Molluscum Contagiosum Pipeline treatment landscape of the report, click here @ Molluscum Contagiosum Pipeline Outlook
Key Takeaways from the Molluscum Contagiosum Pipeline Report
- DelveInsight’s Molluscum Contagiosum Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
- The leading Molluscum Contagiosum Companies are working in the market include Novan, Veloce Biopharma, Verrica Pharmaceuticals, Santalis Healthcare, Synteract Inc, Paidion Research Inc, Instat Consulting Inc, and others
- Promising Molluscum Contagiosum Pipeline Therapies in the various stages in development include SB 206 (Berdazimer Sodium), VBP-245 (Povidone Iodine Topical), SB206 10.3% berdazimer, Canthardin Collodion, and others
- Novans’ new drug candidate, SB 206 is a topically administered drug molecule in development for the treatment of molluscum contagiosum. The phase I and II data demonstrated that SB 206 for the treatment of molluscum contagiosum has beneficial effects on the infection. The drug works on the nitric oxide mechanism of action, where it act as nitric oxide donor to subsequently destroy the virus.
- Veloce’s drug VBP-245 is currently being evaluated for the treatment of Molluscum Contagiosum and has demonstrated good safety and efficacy profile in phase I trials. VBP-245 is an antiviral drug that inhibits the HN protein responsible for virus attachment to the host cells.
Molluscum Contagiosum Overview
Molluscum Contagiosum is a common viral infection of skin that is characterized by pinkish, firm, round, and painless bumps over the skin. The size of the bump can vary from a few mm to 2-5 mm in diameter. The disease is caused by poxvirus Molluscum contagiosum. The lesion becomes red, swollen, and itchy at times and can spread to other areas of the body when scratched (autoinoculation).
For further information, refer to the detailed Molluscum Contagiosum Unmet Needs, Molluscum Contagiosum Market Drivers, and Molluscum Contagiosum Market Barriers, click here for Molluscum Contagiosum Ongoing Clinical Trial Analysis
Molluscum Contagiosum Emerging Drugs Profile
- SB 206 (Berdazimer Sodium): Novan Inc
- VBP-245 (Povidone Iodine Topical): Veloce Biopharma
Molluscum Contagiosum Pipeline Therapeutics Assessment
There are approx. 10+ Molluscum Contagiosum companies which are developing the therapies for Molluscum Contagiosum. The Molluscum Contagiosum companies which have their Molluscum Contagiosum drug candidates in the most advanced stage, i.e. phase III include, Novan Inc.
Request a sample and discover the recent advances in Molluscum Contagiosum Ongoing Clinical Trial Analysis and Medications, click here @ Molluscum Contagiosum Treatment Landscape
Molluscum Contagiosum Pipeline Segmentation
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Some of the Companies in the Molluscum Contagiosum Therapeutics Market include-
Novan, Veloce Biopharma, Verrica Pharmaceuticals, Santalis Healthcare, Synteract Inc, Paidion Research Inc, Instat Consulting Inc, and others
Dive deep into rich insights for drugs for Molluscum Contagiosum Pipeline, click here @ Molluscum Contagiosum Unmet Needs and Analyst Views
Scope of the Molluscum Contagiosum Pipeline Report
- Coverage- Global
- Molluscum Contagiosum Companies- Novan, Veloce Biopharma, Verrica Pharmaceuticals, Santalis Healthcare, Synteract Inc, Paidion Research Inc, Instat Consulting Inc, and others
- Molluscum Contagiosum Pipeline Therapies- SB 206 (Berdazimer Sodium), VBP-245 (Povidone Iodine Topical), SB206 10.3% berdazimer, Canthardin Collodion, and others
- Molluscum Contagiosum Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Molluscum Contagiosum Mergers and acquisitions, Molluscum Contagiosum Licensing Activities @ Molluscum Contagiosum Emerging Drugs, and Recent Trends
Table of Content
- Introduction
- Executive Summary
- Molluscum Contagiosum: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Molluscum Contagiosum – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Molluscum Contagiosum Collaboration Deals
- Late Stage Products (Phase III)
- SB 206 (Berdazimer Sodium): Novan
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- VBP-245 (Povidone Iodine Topical): Veloce Biopharma
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Molluscum Contagiosum Analyst Views
- Molluscum Contagiosum Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services